MedTrace Logo

Optimizing Cimzia in Crohn's Patients

NCT01024647 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-11-05

No results posted yet for this study

Summary

The purpose of this study is to determine if increasing the dose and/or dosing frequency of certolizumab pegol (Cimzia) is effective in regaining and optimizing response in patients with moderate to severe Crohn's disease.

Conditions

Interventions

BIOLOGICAL

certolizumab pegol

certolizumab pegol 200 mg every 2 weeks

BIOLOGICAL

certolizumab pegol

certolizumab pegol 400 mg every 2 weeks

BIOLOGICAL

certolizumab pegol

certolizumab pegol 400 mg every 4 weeks

BIOLOGICAL

certolizumab pegol

certolizumab pegol 400 mg every 2 weeks

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Atlanta Gastroenterology Associates

    lead OTHER

Principal Investigators

  • Douglas C Wolf, MD · Atlanta Gastroenterology Associates

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01024647 on ClinicalTrials.gov